rawpixel-com-593598-unsplash.jpg

DESCRIPTION

At Neurognos, we’re connecting Alzheimers patients with next-generation screening and diagnostic tests through the power of Machine Learning (ML). Decoding hidden patterns by using artificial intelligence (AI) to recognize disease-associated patterns among circulating biomarkers, Neurognos is developing simple,  accurate, and noninvasive blood tests for early-Alzheimer's screening and detection. We  are looking to provide key information that empowers doctors and patients so they can treat the disease in the most effective way.

THE PROBLEM

The detection of Alzheimer's disease (AD) remains a critical need not met for millions of people around the world. Since the only truly reliable method for its definitive detection is still post mortem analysis, for that reason, that having a reliable and minimally invasive method to detect Alzheimer's at the right time (before the damage is irreversible) is fundamental for our society.

current scenario

At present, the "gold standard" for the detection of AD involves a battery of neuropsychological tests, positron emission tomography, functional MRI and/or a lumbar puncture procidure. These last 3 technologies are Invasive, expensive and not widely available. Despite all these indirect tests, it is estimated that at least 45% of older adults with the disease do NOT obtain an adequate and accurate diagnosis.

 

Solution

Our solution consists in the development of a minimally invasive test that uses a series of biomarkers in blood that include genes and microRNAs together with a ML algorithm as a discriminator with high specificity and sensitivity that make our test an alternative for the direct detection of AD.

 

OUR TECHNOLOGY / How the ML algorithm works

By training on hundred of Alzheimer-positive samples, our ML algorithm learns which biomarker patterns are associated with the disease and training on healthy samples helps us establish what a normal composition biomarkers should look like. With this process eventually the algorithm is able to discern if the sample is from a healthy  or a Alzheimer patients with a large degree of confidence.  

APOE-Testing.jpg

COMMERCIAL MODEL

Our business model consists in the generation of an information package for the analytical and clinical validation of our technology in order to obtain the corresponding regulatory authorization in the US. which allows us to sell and/or licensing our diagnostic test to pharmaceutical and molecular diagnostic companies in order to distribute our technology to a broader range of laboratories and hospital in the US and the rest of the world.

MARKET Size

The global market for diagnosing Alzheimer's disease reached 9.6 billion dollars in 2014 and is expected to grow to 14.5 billion by 2020 due to the aging of the population. Our initial objective will be 4% of the Chilean and North American market in the first year of sales and grow according to the demand of the product through commercial agreements and business development deals.

MAIN MILESTONES TO THE DATE

  • 1st Functional prototype of AD in brain and cerebrospinal fluid
  • Adjudication of the first public grant for $16.000 USD + be accepted in business accelerator, Austral Incuba
  • Freedom to operate confirmed
  • First clinical study in Clinica Davila to develop our Blood Prototipe
  • 2nd Functional prototype of AD in blood + Adjudication of a second public fund grant for $100.000 USD


 

CORE TEAM

Alejandro Bisquertt, CEO / Founder, Master (c) of Biotechnology Enterprise and Entrepreneurship (Johns Hopkins University) and B.S. in Biochemistry and Molecular Biology (Universidad Catolica de Chile)

David Chamorro, CTO,  M.S. in Molecular diagnosis (Universidad de Chile) and B.S in Biochemistry and Molecular Biology (Universidad Católica de Chile)

Jose Miguel Vega, COO, Civil engineer in bioengineering (Universidad Adolfo Ibáñez)
 

Neurognos Spa
Carlos Antunez 2025, Of 805, Providencia, Chile
www.neurognos.com
alejandro@neurognos.com